Halozyme prices USD 1.30 billion notes and Halozyme Therapeutics stock gains 2.61 percent

Published on 10/02/2026 at 22:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue hit USD 481.00 million, up 47.70 percent year over year. Halozyme Therapeutics stock costs EUR 97.60 on October 2, 2026 versus EUR 95.12.

HALO, US40637H1095, Illustration mit AI erstellt.

Halozyme Therapeutics (ISIN US40637H1095) was trading at EUR 97.60 at Lang & Schwarz on October 2, 2026 at 10:03 p.m. CEST, up 2.61 percent versus the prior close of EUR 95.12. The company priced USD 1.30 billion of convertible senior notes due in 2033 on September 17, 2026, according to Halozyme Therapeutics.

USD 1.30 billion financing priced

The upsized notes carry a 1.50 percent annual interest rate and mature on October 1, 2033. The initial conversion price was USD 139.84, representing a 27.50 percent premium to the company stock's USD 109.68 closing price on September 17, 2026, while the offering was expected to close on September 22, 2026, subject to customary conditions.

The financing gives Halozyme capital for capped-call transactions, repurchases of existing convertible notes and general corporate purposes. The company said the capped calls are intended to reduce potential dilution, but the disclosed terms also state that dilution could still occur above the capped-call price.

Second-quarter revenue rose 47.70 percent

Halozyme reported USD 481.00 million of revenue in the second quarter of 2026, up 47.70 percent from the same quarter a year earlier, according to MarketBeat. The figure also exceeded the USD 402.28 million consensus estimate by USD 78.72 million, a 19.57 percent difference.

Adjusted earnings per share reached USD 2.28 in the second quarter, compared with USD 1.79 expected. Management set fiscal 2026 adjusted earnings-per-share guidance at USD 8.65-9.00, giving investors a separate benchmark for the financing and the royalty-driven growth story.

Analyst targets trail the market price

MarketBeat reported nine Buy ratings, three Holds and one Sell among 13 analysts, with an average 12-month target of USD 91.20. The same overview cited TD Cowen raising its target from USD 96.00 to USD 105.00 and Leerink Partners lifting its target from USD 83.00 to USD 110.00 in notes dated August 7, 2026.

That consensus target sits below the latest primary-market quote of USD 109.86, while the target revisions show that analyst views are not uniform. The valuation debate therefore rests on whether the 47.70 percent quarterly revenue growth can support the higher end of fiscal 2026 guidance.

HALO remains below its yearly high

HALO was trading at EUR 97.60 at Lang & Schwarz on October 2, 2026 at 10:03 p.m. CEST, after the Xetra session and in the after-hours phase, versus a prior close of EUR 95.12 on October 1, 2026. The primary Nasdaq listing showed a 52-week range of USD 61.23 to USD 116.85 and a market capitalization of USD 13.0 billion as of October 2, 2026.